Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant bins » significant bias (Expand Search), significant bit (Expand Search), significant hits (Expand Search)
bins decrease » point decrease (Expand Search), sizes decrease (Expand Search), nn decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant bins » significant bias (Expand Search), significant bit (Expand Search), significant hits (Expand Search)
bins decrease » point decrease (Expand Search), sizes decrease (Expand Search), nn decrease (Expand Search)
-
601
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
602
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
603
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
604
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
605
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
606
Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula...
Published 2025“…P values were calculated via the two-sided Wilcoxon test. ns, not significant, **, P < 0.01 and ****, P < 0.0001. (G) Feature plot showing LDLR expression levels in C1Q+ macrophages between CAG and control samples.…”
-
607
-
608
Data Sheet 1_Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation—patients with AF produce lower SN levels than healthy individuals: the SAFE r...
Published 2025“…Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, p = 0.032). …”
-
609
The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin...
Published 2025“…The substantial and differential decrease in testosterone and SHBG levels does not explain our previous finding of no detected decrease in risky sexual behavior or sexual function for DMPA-IM or NET-EN users from D0 to 25W. …”
-
610
-
611
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
612
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
613
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
614
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
615
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
616
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
617
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Published 2025Subjects: -
618
-
619
-
620